Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why ChemoCentryx Shares Plunged

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of ChemoCentryx (NASDAQ: CCXI  )  -- a biopharmaceutical company focused on developing oral autoimmune and inflammatory disorder therapies, and treatments for cancer -- slumped as much as 27% after reporting top-line interim mid-stage results for CCX140 in patients with diabetic nephropathy.

So what: According to the company's press release, CCX140, a CCR2 inhibitor, was well tolerated in trials. After 12 weeks, the 5 mg dosing group exhibited a 12% reduction in urinary albumin creatinine ratio relative to a 1% increase for the placebo while the 10 mg dose demonstrated an 8% reduction. While these results sounds decent and would show that CCX140 is having some effect on protein levels within diabetic patients' damaged kidneys, the results didn't match expectations outlined in August of a 20% reduction in protein levels, as noted by senior biotech columnist at TheStreet, Adam Feuerstein.

Now what: ChemoCentryx plans to continue its ongoing phase 2 study of CCX140 given the prospect of success in a predefined subset of patients, but it's been a dismal month for the company overall. Last month, ChemoCentryx saw nearly half of its market value evaporate after the failure of vercirnon in late-stage trials for the treatment of Crohn's disease, and now this. Clearly not all hope is lost and CCX140 may still prove noteworthy, but in the interim ChemoCentryx has lost nearly all of the catalysts that would push its stock higher.

The allure of a big rebound in ChemoCentryx shares is almost certainly going to attract more risk-loving investors over the coming months. But, let today's drop serve as a reminder that solid companies selling at depressed prices are what have consistently helped generations of the world's most successful investors preserve capital, minimize risk, and achieve long-term, market-trampling returns. For one such company, read our free report: "The One REMARKABLE Stock to Own Now." Just click here to get started.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2630805, ~/Articles/ArticleHandler.aspx, 9/28/2016 4:54:09 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 12.84 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
CCXI $5.64 Down -0.23 -3.92%
ChemoCentryx CAPS Rating: ***